131I-Weimeisheng

Manufacturer and Development
¹³¹I-Weimeisheng, also known as ¹³¹I-Tumor Necrosis Therapy monoclonal antibody (mAb) injection, is a radiolabeled chimeric antibody. It was originally developed at the University of Southern California and later commercialized in China by Shanghai Meien Biotechnology and the China Isotope & Radiation Corporation (CIRC). Classified as a ‘me-too plus’ radiolabeled analogue, it incorporates advanced features to target intracellular DNA effectively. This innovative therapeutic agent was officially launched in China in 2006.

Clinical Applications
This drug is primarily utilized for radioimmunotherapy in patients with advanced lung cancer. It is specifically indicated for cases where conventional radioactive chemotherapy has failed to provide control or for individuals experiencing relapses of advanced lung cancer.

Market Availability and Pricing
Currently, ¹³¹I-Weimeisheng is exclusively available in China. Pricing details are not disclosed publicly, making accessibility limited to the Chinese market.

Competitive Landscape
The drug faces minimal competition due to the lack of alternative treatments at the late-stage disease level. Its unique targeting mechanism positions it as a crucial option in its specific clinical application.

Global Interest
To date, no significant interest or efforts have been made to develop or introduce this drug outside China, limiting its global impact despite its potential.